SCHEDULE: Anson Funds Discloses 4.9% Passive Stake in Sellas Life Sciences
Ownership Disclosure
Anson Funds and its affiliates have reported a 4.9% passive beneficial ownership stake in Sellas Life Sciences Group, Inc. as of December 31, 2025.
Summary
- Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam collectively reported beneficial ownership of 7,481,178 shares of Common Stock in Sellas Life Sciences Group, Inc.
- This ownership represents 4.9% of the outstanding Common Stock of Sellas Life Sciences Group, Inc.
- The percentage is calculated based on 142,442,239 Common Stock issued and outstanding as of November 12, 2025, plus 7,481,178 Common Stock receivable upon exercise of warrants.
- The reporting persons hold these securities in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- Warrants held by the reporting persons include a beneficial ownership limitation, preventing exercise if it would result in ownership exceeding 4.99% of the outstanding Common Stock.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant passive investment by Anson Funds indicates a vote of confidence in Sellas Life Sciences Group, Inc. without implying any immediate operational changes or control battles.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- Tony Moore, Manager for Anson Funds Management LP and Anson Management GP LLC, certified that the information is true, complete, and correct.
- Amin Nathoo and Moez Kassam, Directors for Anson Advisors Inc., certified the accuracy of the information.
- The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that a 4.9% passive stake by an investment firm like Anson Funds in a life sciences company such as Sellas Life Sciences Group, Inc. indicates a notable, albeit non-controlling, investment interest. This level of ownership suggests confidence in the company's long-term prospects without an intent to engage in corporate governance or strategic direction, which is common for institutional investors seeking exposure to specific sectors or growth opportunities.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders may view this as a positive sign of institutional interest and validation for Sellas Life Sciences Group, Inc.'s stock.
- The passive nature of the stake suggests no immediate impact on the company's management or strategic direction.
Key Dates
| Date | Description |
|---|---|
| 2025-11-14 | Date of Joint Filing Agreement execution. |
| 2025-12-31 | Date of event which requires the filing of this statement (beneficial ownership calculation date). |
| 2026-02-17 | Date of signing the Schedule 13G Amendment No. 1. |
Keywords
Sellas Life Sciences Group, Anson Funds, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Passive Stake, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.